The current paradigm of cancer management relies on imaging modalities and tissue biopsy to characterize the tumor landscape and devise treatment. As a complementary approach to non-invasive cancer detection, liquid biopsy is gaining interest through the detection of biomarkers circulating in body fluids. However, the wider use of liquid biopsy in the clinical setting is often hindered by limited technologies that can reliably and sensitively detect trace biomarkers in bodily fluids. As one of the most promising emerging technologies, digital single-molecule platforms (DSMPs) offer unparallele...
